EA201492177A1 - Очистка идуронат-2-сульфатазы - Google Patents
Очистка идуронат-2-сульфатазыInfo
- Publication number
- EA201492177A1 EA201492177A1 EA201492177A EA201492177A EA201492177A1 EA 201492177 A1 EA201492177 A1 EA 201492177A1 EA 201492177 A EA201492177 A EA 201492177A EA 201492177 A EA201492177 A EA 201492177A EA 201492177 A1 EA201492177 A1 EA 201492177A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- iuronat
- sulfatase
- cleaning
- protein
- present
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/095—Oxytocins; Vasopressins; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/06—Sulfuric ester hydrolases (3.1.6)
- C12Y301/06013—Iduronate-2-sulfatase (3.1.6.13)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biophysics (AREA)
- Dermatology (AREA)
- Toxicology (AREA)
- Analytical Chemistry (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
В настоящем изобретении, среди прочего, предложены усовершенствованные способы очистки белка I2S, полученного рекомбинантным способом, для ферментозаместительной терапии. Настоящее изобретение частично основано на неожиданном открытии, что рекомбинантный белок I2S может быть очищен от необработанного биологического материала, такого как содержащая I2S клеточная культуральная среда, при помощи способа, включающего применение всего лишь четырех хроматографических колонок.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261666733P | 2012-06-29 | 2012-06-29 | |
PCT/US2013/048561 WO2014005014A2 (en) | 2012-06-29 | 2013-06-28 | Purification of iduronate-2-sulfatase |
Publications (2)
Publication Number | Publication Date |
---|---|
EA201492177A1 true EA201492177A1 (ru) | 2015-06-30 |
EA034549B1 EA034549B1 (ru) | 2020-02-19 |
Family
ID=49778401
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA202090044A EA202090044A1 (ru) | 2012-06-29 | 2013-06-28 | Очистка идуронат-2-сульфатазы |
EA201492177A EA034549B1 (ru) | 2012-06-29 | 2013-06-28 | Очистка идуронат-2-сульфатазы |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA202090044A EA202090044A1 (ru) | 2012-06-29 | 2013-06-28 | Очистка идуронат-2-сульфатазы |
Country Status (38)
Country | Link |
---|---|
US (6) | US9051556B2 (ru) |
EP (2) | EP3441398A1 (ru) |
JP (4) | JP6171007B2 (ru) |
KR (5) | KR101380740B1 (ru) |
CN (3) | CN107596358A (ru) |
AR (1) | AR091647A1 (ru) |
AU (3) | AU2013282395C1 (ru) |
BR (1) | BR112014032567B1 (ru) |
CA (2) | CA2877517C (ru) |
CL (1) | CL2014003567A1 (ru) |
CO (1) | CO7240396A2 (ru) |
CR (1) | CR20140588A (ru) |
CY (1) | CY1121519T1 (ru) |
DK (1) | DK2867245T3 (ru) |
DO (1) | DOP2014000294A (ru) |
EA (2) | EA202090044A1 (ru) |
ES (1) | ES2689468T3 (ru) |
GT (1) | GT201400303A (ru) |
HK (4) | HK1209431A1 (ru) |
HR (1) | HRP20181897T1 (ru) |
HU (1) | HUE040769T2 (ru) |
IL (4) | IL236315A (ru) |
LT (1) | LT2867245T (ru) |
MX (3) | MX366906B (ru) |
MY (3) | MY180287A (ru) |
NZ (3) | NZ743910A (ru) |
PE (1) | PE20150720A1 (ru) |
PH (3) | PH12014502871A1 (ru) |
PL (1) | PL2867245T3 (ru) |
PT (1) | PT2867245T (ru) |
RS (1) | RS58005B1 (ru) |
SG (2) | SG11201408761VA (ru) |
SI (1) | SI2867245T1 (ru) |
TR (1) | TR201815811T4 (ru) |
TW (2) | TWI587869B (ru) |
UA (1) | UA121959C2 (ru) |
WO (1) | WO2014005014A2 (ru) |
ZA (2) | ZA201409397B (ru) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5901877B2 (ja) | 2007-07-27 | 2016-04-13 | アーメイゲン・テクノロジーズ・インコーポレイテッドArmagen Technologies, Inc. | 中枢神経系のα−L−イデュロニダーゼ活性を増加させるための方法および組成物 |
KR101158673B1 (ko) | 2011-06-24 | 2012-07-03 | 주식회사 지씨바이오 | 재조합 인간 이듀로네이트-2-설파타아제를 포함하는 조성물, 제제 및 이의 제조방법 |
US20160145589A1 (en) | 2011-06-24 | 2016-05-26 | Green Cross Corporation | Composition and formulation comprising recombinant human iduronate-2-sulfatase and preparation method thereof |
KR101380740B1 (ko) | 2012-06-29 | 2014-04-11 | 쉐어 휴먼 제네텍 세러피스, 인코포레이티드 | 이듀로네이트-2-설파타제의 정제 |
US9150841B2 (en) | 2012-06-29 | 2015-10-06 | Shire Human Genetic Therapies, Inc. | Cells for producing recombinant iduronate-2-sulfatase |
AU2017316955B2 (en) | 2016-08-25 | 2022-03-03 | Jcr Pharmaceuticals Co., Ltd. | Method for producing antibody fusion protein |
CN106282231B (zh) * | 2016-09-06 | 2020-01-03 | 陕西慧康生物科技有限责任公司 | 粘多糖贮积症ii型动物模型的构建方法及应用 |
CN106428420B (zh) * | 2016-10-17 | 2018-08-21 | 上海江南长兴造船有限责任公司 | 一种用于超大型集装箱船止裂钢舱口围的安装的方法 |
MA50746A (fr) | 2017-10-02 | 2020-08-12 | Denali Therapeutics Inc | Protéines de fusion comprenant des enzymes d'enzymothérapie substitutive |
US20220002688A1 (en) * | 2018-12-20 | 2022-01-06 | Armagen, Inc. | Purification of iduronate-2-sulfatase immunoglobulin fusion protein |
CN116670270A (zh) * | 2020-10-23 | 2023-08-29 | 阿雷克森制药公司 | 控制碱性磷酸酶制造期间的总唾液酸含量(tsac)的方法 |
Family Cites Families (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK6488D0 (da) | 1988-01-07 | 1988-01-07 | Novo Industri As | Enzymer |
US5310646A (en) | 1988-05-13 | 1994-05-10 | Regents Of The University Of Minnesota | Method for the detection of mucopolysaccharide storage diseases |
US5932211A (en) | 1991-11-12 | 1999-08-03 | Women's And Children's Hospital | Glycosylation variants of iduronate 2-sulfatase |
EP0750511B1 (en) | 1994-03-16 | 2003-06-11 | The Regents Of The University Of California | Treating inflammation via the administration of specific sulfatase enzymes and/or sulfation inhibitor |
US5863782A (en) | 1995-04-19 | 1999-01-26 | Women's And Children's Hospital | Synthetic mammalian sulphamidase and genetic sequences encoding same |
DE19527054A1 (de) | 1995-07-26 | 1997-01-30 | Behringwerke Ag | Verfahren zur Charakterisierung der Glycosylierung von Glycoproteinen sowie zur in-vitro Bestimmung der Bioverfügbarkeit von Glycoproteinen |
EP2221361A3 (en) | 1996-08-30 | 2011-02-09 | Life Technologies Corporation | Method for producing a polypeptide in vitro in mammalian cells in a protein-free and serum-free culture medium |
US7368531B2 (en) | 1997-03-07 | 2008-05-06 | Human Genome Sciences, Inc. | Human secreted proteins |
US7083793B2 (en) | 1999-02-26 | 2006-08-01 | Millennium Pharmaceuticals, Inc. | Tango 243 polypeptides and uses thereof |
EP2301947A3 (en) | 1999-02-26 | 2011-11-23 | Millennium Pharmaceuticals, Inc. | Secreted proteins and uses thereof |
EP1171615B1 (en) | 1999-04-26 | 2006-12-13 | Genentech, Inc. | Cell culture process for glycoproteins |
JP2002017376A (ja) | 1999-07-08 | 2002-01-22 | Herikkusu Kenkyusho:Kk | 分泌蛋白質、または膜蛋白質 |
AU7099200A (en) | 1999-09-03 | 2001-04-10 | Human Genome Sciences, Inc. | 52 human secreted proteins |
US6780627B1 (en) | 2000-01-31 | 2004-08-24 | Millennium Pharmaceuticals, Inc. | 22438, 23553, 25278, and 26212 novel human sulfatases |
EP1255819A2 (en) | 2000-02-17 | 2002-11-13 | Incyte Genomics, Inc. | Human kinases |
JP2003527851A (ja) | 2000-03-17 | 2003-09-24 | ヒューマン ジノーム サイエンシーズ, インコーポレイテッド | 7つのヒト卵巣および卵巣癌関連タンパク質 |
CA2405709A1 (en) | 2000-04-12 | 2001-10-25 | Human Genome Sciences, Inc. | Albumin fusion proteins |
US20030148920A1 (en) | 2000-12-27 | 2003-08-07 | Steven Rosen | Sulfatases and methods of use thereof |
WO2002098455A2 (en) | 2001-06-07 | 2002-12-12 | Hemebiotech A/S | Production of recombinant human arylsulfatase a |
US7323553B2 (en) | 2002-04-26 | 2008-01-29 | Genentech, Inc. | Non-affinity purification of proteins |
US6890736B1 (en) | 2002-09-20 | 2005-05-10 | Immunex Corporation | Methods for producing proteins in cultured cells |
WO2004058800A2 (en) * | 2002-12-23 | 2004-07-15 | Bristol-Myers Squibb Company | Mammalian cell culture processes for protein production |
JP4606712B2 (ja) * | 2003-01-08 | 2011-01-05 | マサチューセッツ インスティテュート オブ テクノロジー | 2−oスルファターゼ組成物および関連の方法 |
AU2004210936C1 (en) | 2003-02-11 | 2010-12-02 | Takeda Pharmaceutical Company Limited | Diagnosis and treatment of Multiple Sulfatase Deficiency and other using a Formylglycine Generating Enzyme (FGE) |
US20050019914A1 (en) | 2003-07-24 | 2005-01-27 | Aventis Pharma Deutschland Gmbh | Perfusion process for producing erythropoietin |
NZ576986A (en) | 2004-01-30 | 2010-12-24 | Shire Pharmaceuticals Ireland Ltd | Production and purification of recombinant arylsulfatase A |
WO2005113765A2 (en) | 2004-05-06 | 2005-12-01 | Biomarin Pharmaceutical Inc. | Methods of activation of sulfatases and methods and compositions of using the same |
EP1885753B1 (en) | 2005-06-03 | 2011-07-27 | Ares Trading S.A. | Production of recombinant Il-18 binding protein |
KR20080111487A (ko) | 2006-03-20 | 2008-12-23 | 메다렉스, 인코포레이티드 | 단백질 정제 방법 |
JP4458377B2 (ja) | 2007-06-29 | 2010-04-28 | キヤノン株式会社 | プロセスカートリッジ及び電子写真画像形成装置 |
US20130195888A1 (en) | 2007-11-30 | 2013-08-01 | Abbvie | Ultrafiltration and diafiltration formulation methods for protein processing |
CN105274072A (zh) | 2008-01-18 | 2016-01-27 | 生物马林药物股份有限公司 | 制备活性高度磷酸化人溶酶体硫酸酯酶及其应用 |
WO2011044542A1 (en) | 2009-10-09 | 2011-04-14 | Armagen Technologies, Inc. | Methods and compositions for increasing iduronate 2-sulfatase activity in the cns |
JPWO2011108451A1 (ja) * | 2010-03-01 | 2013-06-27 | 日本ケミカルリサーチ株式会社 | 遺伝子ノックアウト細胞を用いた組換え体リソソーム酵素の製造方法 |
JP6063380B2 (ja) * | 2010-06-25 | 2017-01-18 | シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド | サンフィリポ症候群b型の処置 |
RU2660348C2 (ru) | 2010-06-25 | 2018-07-05 | Шир Хьюман Дженетик Терапис, Инк. | Способы и композиции для доставки в цнс идуронат-2-сульфатазы |
AR082319A1 (es) | 2010-07-22 | 2012-11-28 | Biomarin Pharm Inc | Produccion de una n-acetilgalactosamina-6-sulfatasa humana activa altamente fosforilada y sus usos |
EP2623118A4 (en) * | 2010-09-28 | 2014-05-07 | Kyoritsu Seiyaku Corp | MUCOSAL ADJUVANT COMPOSITION |
WO2012101671A1 (en) | 2011-01-25 | 2012-08-02 | Jcr Pharmaceuticals Co., Ltd. | Method for production of human recombinant iduronate 2-sulfatase |
US20140022222A1 (en) | 2011-01-31 | 2014-01-23 | Huei Pei Kuo | Diffuser with a dynamically tunable scattering angle |
KR101158673B1 (ko) | 2011-06-24 | 2012-07-03 | 주식회사 지씨바이오 | 재조합 인간 이듀로네이트-2-설파타아제를 포함하는 조성물, 제제 및 이의 제조방법 |
US9150841B2 (en) | 2012-06-29 | 2015-10-06 | Shire Human Genetic Therapies, Inc. | Cells for producing recombinant iduronate-2-sulfatase |
US20140004097A1 (en) | 2012-06-29 | 2014-01-02 | Shire Human Genetic Therapies, Inc. | Method of producing recombinant iduronate-2-sulfatase |
KR101380740B1 (ko) | 2012-06-29 | 2014-04-11 | 쉐어 휴먼 제네텍 세러피스, 인코포레이티드 | 이듀로네이트-2-설파타제의 정제 |
KR20190062745A (ko) | 2017-11-29 | 2019-06-07 | 주식회사 위니플 | 쇼핑몰 모바일앱 빌더 |
-
2012
- 2012-09-07 KR KR1020120099511A patent/KR101380740B1/ko active IP Right Grant
-
2013
- 2013-03-14 US US13/829,706 patent/US9051556B2/en active Active
- 2013-06-28 EA EA202090044A patent/EA202090044A1/ru unknown
- 2013-06-28 NZ NZ743910A patent/NZ743910A/en unknown
- 2013-06-28 CN CN201710840704.3A patent/CN107596358A/zh active Pending
- 2013-06-28 CN CN201380042665.2A patent/CN104583225A/zh active Pending
- 2013-06-28 UA UAA201413826A patent/UA121959C2/uk unknown
- 2013-06-28 DK DK13809853.8T patent/DK2867245T3/en active
- 2013-06-28 MX MX2016001228A patent/MX366906B/es unknown
- 2013-06-28 RS RS20181324A patent/RS58005B1/sr unknown
- 2013-06-28 JP JP2015520567A patent/JP6171007B2/ja active Active
- 2013-06-28 SG SG11201408761VA patent/SG11201408761VA/en unknown
- 2013-06-28 BR BR112014032567-7A patent/BR112014032567B1/pt active IP Right Grant
- 2013-06-28 MY MYPI2016000157A patent/MY180287A/en unknown
- 2013-06-28 MX MX2015000190A patent/MX336715B/es unknown
- 2013-06-28 TW TW105120026A patent/TWI587869B/zh active
- 2013-06-28 ES ES13809853.8T patent/ES2689468T3/es active Active
- 2013-06-28 NZ NZ733366A patent/NZ733366A/en unknown
- 2013-06-28 HU HUE13809853A patent/HUE040769T2/hu unknown
- 2013-06-28 TW TW102123353A patent/TWI553120B/zh active
- 2013-06-28 EP EP18193801.0A patent/EP3441398A1/en active Pending
- 2013-06-28 EP EP13809853.8A patent/EP2867245B1/en active Active
- 2013-06-28 CN CN201710840314.6A patent/CN107596357A/zh active Pending
- 2013-06-28 WO PCT/US2013/048561 patent/WO2014005014A2/en active Application Filing
- 2013-06-28 CA CA2877517A patent/CA2877517C/en active Active
- 2013-06-28 SG SG10201703489VA patent/SG10201703489VA/en unknown
- 2013-06-28 PT PT13809853T patent/PT2867245T/pt unknown
- 2013-06-28 PL PL13809853T patent/PL2867245T3/pl unknown
- 2013-06-28 TR TR2018/15811T patent/TR201815811T4/tr unknown
- 2013-06-28 MY MYPI2019006401A patent/MY192068A/en unknown
- 2013-06-28 AU AU2013282395A patent/AU2013282395C1/en active Active
- 2013-06-28 LT LTEP13809853.8T patent/LT2867245T/lt unknown
- 2013-06-28 NZ NZ703093A patent/NZ703093A/en unknown
- 2013-06-28 CA CA3008945A patent/CA3008945A1/en not_active Abandoned
- 2013-06-28 PE PE2014002539A patent/PE20150720A1/es active IP Right Grant
- 2013-06-28 EA EA201492177A patent/EA034549B1/ru active IP Right Maintenance
- 2013-06-28 SI SI201331176T patent/SI2867245T1/sl unknown
- 2013-06-28 MY MYPI2014003472A patent/MY157087A/en unknown
- 2013-07-01 AR ARP130102350 patent/AR091647A1/es not_active Application Discontinuation
- 2013-09-26 KR KR1020130114704A patent/KR20140004603A/ko active Search and Examination
-
2014
- 2014-12-17 IL IL236315A patent/IL236315A/en active IP Right Grant
- 2014-12-17 CR CR20140588A patent/CR20140588A/es unknown
- 2014-12-19 DO DO2014000294A patent/DOP2014000294A/es unknown
- 2014-12-19 ZA ZA201409397A patent/ZA201409397B/en unknown
- 2014-12-22 PH PH12014502871A patent/PH12014502871A1/en unknown
- 2014-12-26 CO CO14284199A patent/CO7240396A2/es unknown
- 2014-12-29 CL CL2014003567A patent/CL2014003567A1/es unknown
- 2014-12-29 GT GT201400303A patent/GT201400303A/es unknown
-
2015
- 2015-01-07 MX MX2019008914A patent/MX2019008914A/es unknown
- 2015-03-30 US US14/673,607 patent/US9492511B2/en active Active
- 2015-10-14 HK HK15110042.0A patent/HK1209431A1/xx unknown
- 2015-10-16 PH PH12015502408A patent/PH12015502408A1/en unknown
- 2015-10-28 HK HK15110643.3A patent/HK1209767A1/xx unknown
-
2016
- 2016-01-27 AU AU2016200469A patent/AU2016200469B2/en active Active
- 2016-03-24 JP JP2016060910A patent/JP6505629B2/ja active Active
- 2016-09-28 US US15/279,018 patent/US10344270B2/en active Active
- 2016-11-03 IL IL248727A patent/IL248727A0/en active IP Right Grant
-
2018
- 2018-01-11 AU AU2018200230A patent/AU2018200230B2/en active Active
- 2018-03-30 JP JP2018067404A patent/JP2018121645A/ja not_active Withdrawn
- 2018-05-17 ZA ZA2018/03289A patent/ZA201803289B/en unknown
- 2018-07-05 HK HK18108732.6A patent/HK1249026A1/zh unknown
- 2018-07-05 HK HK18108734.4A patent/HK1249027A1/zh unknown
- 2018-08-21 IL IL261264A patent/IL261264B/en unknown
- 2018-11-14 HR HRP20181897TT patent/HRP20181897T1/hr unknown
- 2018-11-28 CY CY20181101263T patent/CY1121519T1/el unknown
-
2019
- 2019-05-20 US US16/417,440 patent/US20190359958A1/en not_active Abandoned
- 2019-05-28 KR KR1020190062745A patent/KR20190064542A/ko active Application Filing
-
2020
- 2020-01-02 PH PH12020500027A patent/PH12020500027A1/en unknown
- 2020-03-05 JP JP2020037811A patent/JP2020105209A/ja active Pending
- 2020-11-06 US US17/092,034 patent/US11530393B2/en active Active
- 2020-12-16 KR KR1020200176714A patent/KR20200143339A/ko not_active IP Right Cessation
-
2021
- 2021-10-06 IL IL287057A patent/IL287057A/en unknown
- 2021-12-28 KR KR1020210189927A patent/KR20220002227A/ko not_active Application Discontinuation
-
2022
- 2022-11-03 US US18/052,442 patent/US20240043817A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12020500027A1 (en) | Purification of iduronate-2-sulfatase | |
MX2020003798A (es) | Metodos para la purificacion de arilsulfatasa a. | |
NZ743008A (en) | Compositions and methods for internalizing enzymes | |
BR112015019879A2 (pt) | Composições de espécies de variantes moduladas de lisina e métodos para produção e uso das mesmas | |
WO2017024317A3 (en) | Methods to induce targeted protein degradation through bifunctional molecules | |
IN2012DN00801A (ru) | ||
EA201391157A1 (ru) | Антагонисты pcsk9 | |
MX2013003681A (es) | Ácidos nucleicos manipulados y métodos de uso de los mismos. | |
EA201492185A1 (ru) | Способ получения рекомбинантной идуронат-2-сульфатазы | |
WO2012031263A3 (en) | Cell culture system for bioreactor scale-up of cells | |
FI20115328A0 (fi) | Uusia kutinaaseja, niiden tuottaminen ja käytöt | |
MY180183A (en) | Methods and compositions for preventing norleucine misincorporation into proteins | |
EA201590778A1 (ru) | ОЧИСТКА КОМБИНИРОВАННОЙ ГАЛАКТОЦЕРЕБРОЗИД-β-ГАЛАКТОЗИДАЗЫ ЧЕЛОВЕКА (rhGALC) | |
MX2015010887A (es) | Formulaciones y metodos para aumentar la produccion de proteinas recombinantes. | |
MX341733B (es) | Purificacion de inhibidor de proteasa alfa1 derivado de cultivo celular. | |
MX2021016092A (es) | Metodos de purificacion de proteinas. | |
RU2012143225A (ru) | Способ выделения и очистки иммобилизованного фермента | |
TH160179B (th) | การทำไอดิลโรเนต-2-ซัลฟาเตสให้บริสุทธิ์ | |
FI20115976A0 (fi) | Proteolyyttisen entsyymin käyttö | |
TH160179A (th) | การทำไอดิลโรเนต-2-ซัลฟาเตสให้บริสุทธิ์ |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MD4A | Opposition filed against granted eurasian patent | ||
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ KG TJ TM |
|
LC4A | Partial administrative revocation of a eurasian patent (b2) |